A new editorial paper titled “How to deal with runaway metastatic disease?” has been published in Oncotarget.
In this new editorial, Justine Paris and Guilhem Bousquet from Université Paris Cité, Université Sorbonne Paris Nord, and APHP, Hôpital Avicenne, Oncologie médical, discuss how their research team have shown that PROM2 is a predictive biomarker of distant metastases and shorter survival among patients with stage III melanomas.
More recently, in a large preclinical study using cancer cell lines and various mouse models of human melanomas, the researchers also demonstrated that the runaway metastatic process is closely linked to PROM2 overexpression, through the increase of epithelial-to-mesenchymal transition (EMT) marker expression and ferroptosis resistance.
“We report two critical findings: (i) these findings, initially observed in melanoma, have also been confirmed in renal and breast cancers; (ii) we successfully implemented an original in vivo model of metastatic runaway in order to mimic what occurs in patients,” state the researchers.
More information:
Justine Paris et al, How to deal with runaway metastatic disease?, Oncotarget (2024). DOI: 10.18632/oncotarget.28609
Provided by
Impact Journals LLC
Citation:
Dealing with runaway metastatic disease (2024, August 7)
retrieved 7 August 2024
from https://medicalxpress.com/news/2024-08-runaway-metastatic-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
